Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ATPC vs CDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATPC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

ATPC Overall Winner 6-Pillar Tally: ATPC 3 – 2 CDT (1 Tie) Matrix Metrics: ATPC 4 – 3 CDT

As of Nov 20, 2026, Agape ATP Corporation (ATPC) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ATPC carries a Unified Composite Score of 51.6/100 (HOLD) at $1.16 (N/M Forward P/E, -239.0% operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ATPC earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. CDT 31.6/100 SELL) and 0.83β · 135% Vol risk profile, whereas CDT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ATPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.0); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATPC vs CDT
ATPC NASDAQ Head-to-Head Winner
Agape ATP Corporation Common Stock
Services-Health Services
$1.16
-15.94% 1D
Market Cap $1.4M
TTM Revenue $1.3M
Forward P/E N/M
Beta / 30D Vol 0.83β · 135% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 71.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.5%), weak momentum, RSI 38
RSI-14: 38.0 · SMA20: $1.34 · SMA50: $1.74
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40

6-Pillar Scorecard Institutional Category Breakdown (ATPC 3 – 2 CDT)

Columns: Metric · ATPC · CDT
1. Valuation Multiples ATPC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.0x N/M
2. Growth & Scale CDT
Revenue Growth (YoY) -93.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.3M N/A
Market Cap $1.4M $507,528
3. Profitability & Quality CDT
Gross Margin 59.2% N/A
Operating Margin -239.0% 0.0%
Net Profit Margin -86.3% 0.0%
Return on Equity (ROE) -5.5% -69.7%
4. Balance Sheet & Cash Flow ATPC
Cash Generation (TTM) -$1.4M N/A
Cash Flow Margin -103.0% N/A
Net Cash / Leverage -$40,377 Net Debt (0.01x D/E) $435,000 Net Debt (0.01x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATPC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Packaged Foods Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATPC (4) vs CDT (3)
Institutional Metric ATPC CDT Criterion Row Edge
Market Capitalization
Scale
$1.4M $507,528 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-93.4% +0.0% Higher Growth CDT
Operating Margin (TTM)
Profitability
-239.0% 0.0% Higher Margin CDT
Net Profit Margin
Profitability
-86.3% 0.0% Higher Margin CDT
Return on Equity (ROE)
Capital Efficiency
-5.5% -69.7% Higher ROE ATPC
52-Week Range Position
Momentum
13% ($0–$8) 2% ($0–$11) Stronger Trend ATPC
Beta / 30D Volatility
Risk Regime
0.83β · 135% Vol -17.75β · 10175% Vol Lower Realized Risk ATPC
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ATPC
Trailing 12M Revenue (USD)
Operating Scale
$1.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
59.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M (-$40,377 Net Debt (0.01x D/E)) N/A ($435,000 Net Debt (0.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +95.1 pp
ATPC: -18.31% · CDT: +76.79%
3M Horizon ATPC +39.5 pp
ATPC: -51.26% · CDT: -90.76%
6M Horizon ATPC +19.83 pp
ATPC: -58.27% · CDT: -78.1%
1Y Horizon ATPC +76.01 pp
ATPC: -10.77% · CDT: -86.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATPC vs CDT. Trailing 12-month operating profitability (ATPC -239.0% vs CDT 0.0%) and valuation multiples (ATPC N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ATPC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.3M
Gross Margin59.2%
Op. Margin-239.0%
ROE / Fwd P/E-5.5% · N/M
CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATPC Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $1.4M market capitalization and -239.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATPC vs CDT Key Questions & Quantitative Answers

As of Nov 20, 2026, Agape ATP Corporation (ATPC) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). ATPC carries a Unified Composite Score of 51.6/100 (HOLD) at $1.16 (N/M Forward P/E, -239.0% operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ATPC earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. CDT 31.6/100 SELL) and 0.83β · 135% Vol risk profile, whereas CDT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ATPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.0); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDT leads the Growth & Scale pillar: ATPC posts -93.4% YoY revenue growth and +0.0% YoY earnings growth on $1.3M TTM revenue (59.2% gross margin, -239.0% operating margin), compared with CDT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ATPC generates $1.3M in USD-normalized revenue versus N/A for CDT. In operating R&D and SG&A reinvestment, ATPC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDT.

ATPC screens cheaper on headline valuation multiples. ATPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.0x EV/Revenue (-103.0% FCF margin), whereas CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATPC (-5.5% ROE) versus CDT (-69.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ATPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.83β · 135% Vol realized risk). By comparison, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.